EAPI.PA

Euroapi SAS

EAPI.PA, France

Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances. It provides their products to pharmaceutical, generic drug manufacturers, animal health product manufacturers, consumer health, nutrition and cosmetic product companies, biotech companies, and distribution companies, as well as contract development and manufacturing organization. The company has a strategic alliance with Abolis Biotechnologies SAS for the development of microbial strains for the synthesis of key intermediates and 20 active ingredients. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.

https://www.euroapi.com/en

Stock Price

€0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
EAPI.PA
stock
EAPI.PA

Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry? simplywall.st

Read more →

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

HOLD

$

Analyst Picks

Strong Buy

1

Buy

0

Hold

2

Sell

2

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.21

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-2.99 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-1.98 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-4.99 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.51

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Euroapi SAS

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.3

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-06-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

€ 0

Short Term Investments

€ 0

Receivables

€ 0

Inventories

€ 0

Total Current Assets

€ 0

Property Plant Equipment

€ 0

Total Assets

€ 0

Payables

€ 0

Short Term Debt

€ 0

Long Term Debt

€ 0

Total Liabilities

€ 0

Equity

€ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

€ 0

Depreciation

€ 0

Change In Working Capital

€ 0

Cash From Operations

€ 0

Capital Expenditures

€ 0

Cash From Investing

€ 0

Cash From Financing

€ 0

Net Change In Cash

€ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.